 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 3 | 6 | | 2013 | 2 | 1 | 3 | | 2014 | 2 | 1 | 3 | | 2015 | 4 | 2 | 6 | | 2016 | 3 | 2 | 5 | | 2017 | 2 | 2 | 4 | | 2018 | 9 | 5 | 14 | | 2019 | 16 | 4 | 20 | | 2020 | 10 | 3 | 13 | | 2021 | 16 | 12 | 28 | | 2022 | 5 | 13 | 18 | | 2023 | 4 | 23 | 27 | | 2024 | 15 | 9 | 24 | | 2025 | 41 | 1 | 42 | | 2026 | 24 | 6 | 30 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Ang MJY, Luo Z, Mitchell MJ. The Modular CAR: Adapting T Cells without Reengineering Them. Cancer Immunol Res. 2026 Oct 05; 14(10):1536-1537.
-
Ahmed S, Martín García-Sancho A, Reguera Ortega JL, Cartron G, Rapoport AP, Izutsu K, Ghesquieres H, Goto H, Palomba ML, Abramson JS, Borchmann P, Jäger U, Kamdar M, Dreyling M, Subklewe M, Dahiya S, Nastoupil LJ, Bar M, Strocchia M, Raggi M, Bueno L, Papuga J, Colicino S, Morschhauser F. Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL. Blood. 2026 Oct 01; 148(14):1789-1799.
-
Pinto N, Künkele A, Albert CM, Taylor MR, Ullom HB, Vitanza NA, Wilson AL, Cole BL, Yeung CCS, Wright JH, Huang W, Wendler J, Seidel K, Brown C, Gustafson J, Rawlings-Rhea SD, Beebe A, Mgebroff S, Gardner RA, Jensen MC, Park JR. The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clin Cancer Res. 2026 Sep 15; 32(18):4062-4074.
-
Keller AL, Dennis KA, Ohlstrom DJ, Parzych SE, Walker ZJ, Novak AJ, Pham-Danis C, Medha TN, Rahkola JT, Boorgula MP, Kohler ME, Sherbenou DW. Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res. 2026 Aug 04; 14(8):1307-1321.
-
Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S. Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Sci Transl Med. 2026 Jul 22; 18(859):eadt9565.
-
Karulkar A, Jain H, Sidharthan N, Bhurani D, Melinkeri S, Boyella PK, Mehta P, Kaul E, Shah S, P K J, Nair C, Bhargava R, Bagal B, Nayak L, Shetty A, Menon H, Boya RR, Abhinav R, Kalra D, Ravikumar S, Thorat J, Purwar S, Shah NN, Fry T, Jain N, Neelapu S, Sengar M, Purwar R. Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety. Blood Cancer J. 2026 Jul 16; 16(1).
-
de Jong D, McGale JP, Robinson TJ, Liao MJ, Das JP, Major A, Capaccione KM, Ladbury C, Mansilla-Soto J, Ma H, Al Feghali KA, Goy AH, Lopci E, Reshef R, Schwartz LH, Houot R, Dercle L. CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment. J Nucl Med. 2026 Jul 01; 67(7):1021-1031.
-
Garcia C, Lyons KU, Contreras JG, Liu T, Donnelly AJ, Novak AJ, Argabright A, Anderson C, Grier A, Smith S, Michlin J, Olusoji J, Mikeska RG, Zhou X, Geng H, Rahkola JT, Patel HN, Jacot JG, Müschen M, D'Alessandro A, Dick JE, Iacobucci I, Mullighan CG, Reisz JA, Phang T, Eric Kohler M, Witkowski MT. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia. 2026 Aug; 40(8):1763-1777.
-
Kamdar M, Bartlett NL. From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma. Blood. 2026 06 11; 147(24):2879-2894.
-
Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N. Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026 06 09; 10(11):3757-3768.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|